Bleomycin in older early-stage favorable Hodgkin lymphoma patients: Analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials

Blood

Volumn 127, Issue 18, 2016, Pages 2189-2192

  Böll, Boris ^a   Goergen, Helen ^a   Behringer, Karolin ^a   Bröckelmann, Paul J ^a   Hitz, Felicitas ^b,c   Kerkhoff, Andrea ^d   Greil, Richard ^e   Von Tresckow, Bastian ^a   Eichenauer, Dennis A ^a   Bürkle, Carolin ^a   Borchmann, Sven ^a   Fuchs, Michael ^a   Diehl, Volker ^a   Engert, Andreas ^a   Borchmann, Peter ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^c SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e Paracelcus Medical University   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE SULFATE; ANTINEOPLASTIC AGENT; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DRUG EFFICACY; FEASIBILITY STUDY; FEMALE; HODGKIN DISEASE; HUMAN; INFECTION RATE; INVESTIGATIVE PROCEDURES; INVOLVED FIELD RADIOTHERAPY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; AGE; CANCER STAGING; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; KAPLAN MEIER METHOD; LUNG DISEASE; MIDDLE AGED; MULTICENTER STUDY; REMISSION;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DACARBAZINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG DISEASES; MALE; MIDDLE AGED; NEOPLASM STAGING; REMISSION INDUCTION; VINBLASTINE;

EID: 84969168174     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-11-681064     Document Type: Article

References (16)

1. Sjöberg J, Halthur C, Kristinsson SY, et al. Progress in Hodgkin lymphoma: a populationbased study on patients diagnosed in Sweden from 1973-2009. Blood. 2012;119(4):990-996.
2. Proctor SJ, Wilkinson J, Jones G, et al. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood. 2012;119(25):6005-6015.
3. Böll B, Bredenfeld H, Görgen H, et al. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood. 2011;118(24):6292-6298.
4. Halbsguth TV, Nogová L, Mueller H, et al. Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood. 2010;116(12): 2026-2032.
5. Ballova V, Rüffer JU, Haverkamp H, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol. 2005;16(1): 124-131.
6. Evens AM, Helenowski I, Ramsdale E, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood. 2012;119(3): 692-695.
7. Evens AM, Hong F, Gordon LI, et al. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol. 2013;161(1):76-86.
8. Böll B, Görgen H, Fuchs M, et al. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol. 2013;31(12): 1522-1529.
9. Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol. 2005;23(30):7614-7620.
10. Canellos GP, Duggan D, Johnson J, Niedzwiecki D. How important is bleomycin in the adriamycin 1 bleomycin 1 vinblastine 1 dacarbazine regimen? J Clin Oncol. 2004;22(8):1532-1533.
11. Stamatoullas A, Brice P, Bouabdallah R, et al. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol. 2015;170(2):179-184.
12. Behringer K, Görgen H, Hitz F, et al; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet. 2015;385(9976):1418-1427.
13. Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363(7): 640-652.
14. Johnson P, Federico M, Fossa A, et al. Response-adapted therapy based on interim FDG-PET scans in advanced Hodgkin lymphoma: first analysis of the safety of de-escalation and efficacy of escalation in the international RATHL Study (CRUK/07/033) [abstract]. Hematol Oncol. 2015;33(Suppl 1):102. Abstract 008.
15. Azoulay E, Herigault S, Levame M, et al. Effect of granulocyte colony-stimulating factor on bleomycin-induced acute lung injury and pulmonary fibrosis. Crit Care Med. 2003;31(5): 1442-1448.
16. Eichenauer DA, Engert A, André M, et al; ESMO Guidelines Working Group. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25(Suppl 3):iii70-iii75.